This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Roger Beerli, PhD
Chief Scientific Officer at NBE-Therapeutics Ltd.


Dr. Roger R. Beerli (CSO, NBE-Therapeutics AG) has over 15 years of experience in discovery, engineering and preclinical development of antibody-based therapeutics. Before he joined NBE-Therapeutics AG, he led therapeutic antibody development programs at Cytos AG, Switzerland, and later at Intercell AG, Austria. Dr. Beerli has published widely in the areas of antibody development and is co-inventor on numerous patents and patent applications.

Agenda Sessions

  • NBE-002, An Anthracycline-based Immune-stimulatory Antibody Drug Conjugate (iADC) Targeting ROR1 for the Treatment of Triple-negative Breast Cancer